Cabaletta Bio, Inc. (CABA) is entering a catalyst-rich period as it advances Rese-cel, its lead autologous CD19-CAR T cell therapy, across multiple autoimmune diseases while preparing for a potential first Biologics License Application submission in 2027.
Autoimmune disorders such as systemic lupus erythematosus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are driven by pathogenic B cells that produce harmful autoantibodies.
For comments and feedback contact: editorial@rttnews.com
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.